Country: Australia
Language: English
Source: Department of Health (Therapeutic Goods Administration)
betahistine dihydrochloride, Quantity: 16 mg
Arrotex Pharmaceuticals Pty Ltd
betahistine dihydrochloride
Tablet, uncoated
Excipient Ingredients: mannitol; microcrystalline cellulose; colloidal anhydrous silica; purified talc; citric acid
Oral
100 tablets, 10 tablets, 25 tablets, 30 tablets, 60 tablets
(S4) Prescription Only Medicine
Meniere's Syndrome as defined by the following core symptoms: vertigo (with nausea/vomiting), hearing loss (hardness of hearing) and tinnitus
Visual Identification: Uncoated, round, biconvex, white to light creamy tablets, with a groove on one surface.; Container Type: Blister Pack; Container Material: PA/Al/PVC/Al - polyamide-aluminium foil-polyvinylchloride/aluminium foil; Container Life Time: 36 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert
Licence status A
2014-08-14